Suppr超能文献

苏格兰加巴喷丁类药物处方、阿片类药物和苯二氮䓬类药物联合处方的趋势及相关死亡情况。

Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland.

机构信息

School of Nursing & Midwifery, Robert Gordon University, Aberdeen, UK.

Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK.

出版信息

Br J Anaesth. 2020 Aug;125(2):159-167. doi: 10.1016/j.bja.2020.05.017. Epub 2020 Jun 19.

Abstract

BACKGROUND

Gabapentinoid drugs (gabapentin and pregabalin) are effective in neuropathic pain, which has a prevalence of ∼7%. Concerns about increased prescribing have implications for patient safety, misuse, and diversion. Drug-related deaths (DRDs) have increased and toxicology often implicates gabapentinoids. We studied national and regional prescribing rates (2006-2016) and identified associated sociodemographic factors, co-prescriptions and mortality, including DRDs.

METHODS

National data from the Information Service Division, NHS Scotland were analysed for prescribing, sociodemographic, and mortality data from the Health Informatics Centre, University of Dundee. DRDs in which gabapentinoids were implicated were identified from National Records of Scotland and Tayside Drug Death Databases.

RESULTS

From 2006 to 2016, the number of gabapentin prescriptions in Scotland increased 4-fold (164 630 to 694 293), and pregabalin 16-fold (27 094 to 435 490). In 2016 'recurrent users' (three or more prescriptions) had mean age 58.1 yr, were mostly females (62.5%), and were more likely to live in deprived areas. Of these, 60% were co-prescribed an opioid, benzodiazepine, or both (opioid 49.9%, benzodiazepine 26.8%, both 17.1%). The age-standardised death rate in those prescribed gabapentinoids was double that in the Scottish population (relative risk 2.16, 95% confidence interval 2.08-2.25). Increases in gabapentinoids contributing to cause of DRDs were reported regionally and nationally (gabapentin 23% vs 15%; pregabalin 21% vs 7%). In Tayside, gabapentinoids were implicated in 22 (39%) of DRDs, 17 (77%) of whom had not received a prescription.

CONCLUSIONS

Gabapentinoid prescribing has increased dramatically since 2006, as have dangerous co-prescribing and death (including DRDs). Older people, women, and those living in deprived areas were particularly likely to receive prescriptions. Their contribution to DRDs may be more related to illegal use with diversion of prescribed medication.

摘要

背景

加巴喷丁类药物(加巴喷丁和普瑞巴林)在治疗神经病理性疼痛方面非常有效,这种疼痛的患病率约为 7%。人们对处方量增加的担忧会影响到患者安全、药物滥用和药物转移等方面。与药物相关的死亡(DRD)有所增加,毒理学通常涉及加巴喷丁类药物。我们研究了全国和地区的处方率(2006-2016 年),并确定了与社会人口统计学因素、共同处方和死亡率相关的因素,包括与药物相关的死亡。

方法

苏格兰国民保健服务信息服务部提供的全国数据,以及邓迪大学卫生信息中心提供的社会人口统计学和死亡率数据,都经过了分析。从苏格兰国家记录和泰赛德药物死亡数据库中确定了与加巴喷丁类药物有关的药物相关死亡。

结果

从 2006 年到 2016 年,苏格兰的加巴喷丁处方数量增加了 4 倍(从 164630 增加到 694293),普瑞巴林增加了 16 倍(从 27094 增加到 435490)。2016 年,“复发性使用者”(三次或更多次处方)的平均年龄为 58.1 岁,大多数为女性(62.5%),更有可能居住在贫困地区。其中,60%的人同时开了阿片类药物、苯二氮䓬类药物或两者(阿片类药物 49.9%,苯二氮䓬类药物 26.8%,两者均为 17.1%)。开处方的加巴喷丁类药物的年龄标准化死亡率是苏格兰人口的两倍(相对风险 2.16,95%置信区间 2.08-2.25)。报告显示,加巴喷丁类药物在全国和地区范围内都导致了药物相关死亡的增加(加巴喷丁 23%比 15%;普瑞巴林 21%比 7%)。在泰赛德,加巴喷丁类药物与 22 例(39%)药物相关死亡有关,其中 17 例(77%)没有处方。

结论

自 2006 年以来,加巴喷丁类药物的处方量大幅增加,同时也出现了危险的共同处方和死亡(包括药物相关死亡)。老年人、女性和生活在贫困地区的人尤其有可能获得处方。他们对药物相关死亡的贡献可能更多地与非法使用和处方药物转移有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验